In this edition of Essential, we look at two major issues facing pharmacy compounding. First is a state-by-state effort by pharma companies to pass laws restricting compounding, and second is a cryptic statement from the FDA about  possible limitations on compounding with GLP-1 ingredients. They’re both Very Big Deals for pharmacists across the country. Links FDA statement on GLP-1 drugs: https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs … and APC’s response: https://a4pc.org/news/apc-responds-to-fdas-glp-1-statement  Stay up to date on our state Compounding Defense Initiative: compounding.com  Join APC today: https://a4pc.org/membership  Find us on social: LinkedIn: https://www.linkedin.com/company/a4pcrx/ Facebook: https://www.facebook.com/a4pcrx/ Instagram: https://www.instagram.com/a4pcrx/